Literature DB >> 23704286

Retooling the creatinine clearance equation to estimate kinetic GFR when the plasma creatinine is changing acutely.

Sheldon Chen1.   

Abstract

It is often desirable to estimate the GFR (eGFR) at the bedside to assess AKI or renal recovery. Current eGFR equations estimate kidney function when the plasma creatinine is stable, but do not work if the plasma creatinine is changing rapidly. To analyze kidney function in the acute setting, a simple formula is proposed that requires only a modest number of inputs that are readily obtainable from clinical laboratory data. The so-called kinetic eGFR (KeGFR) formula is derived from the initial creatinine content, volume of distribution, creatinine production rate, and the quantitative difference between consecutive plasma creatinines over a given time. For that period, the deciphered creatinine excretion then yields the creatinine clearance rate. The additional formula variables needed are any steady-state plasma creatinine, the corresponding eGFR by an empirical formula, and the maximum increase in creatinine per day if anuric. The kinetic formula complements clinical intuition but also adds a quantitative and visual dimension to the assessment of kidney function, demonstrated by its analysis of GFRs underlying the plasma creatinine fluctuations in several scenarios of AKI or renal recovery. Deduced from first principles regarding the physiology of creatinine balance, the KeGFR formula enhances the fundamental clearance equation with the power and versatility to estimate the kidney function when the plasma creatinine is varying acutely.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23704286     DOI: 10.1681/ASN.2012070653

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  63 in total

1.  Optimal methodology is important for optimal pharmacokinetic studies, therapeutic drug monitoring and patient care.

Authors:  Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

Review 2.  Subclinical AKI: ready for primetime in clinical practice?

Authors:  Jill Vanmassenhove; Wim Van Biesen; Raymond Vanholder; Norbert Lameire
Journal:  J Nephrol       Date:  2018-12-06       Impact factor: 3.902

3.  Assessment of the Independent and Synergistic Effects of Fluid Overload and Acute Kidney Injury on Outcomes of Critically Ill Children.

Authors:  Katja M Gist; David T Selewski; John Brinton; Shina Menon; Stuart L Goldstein; Rajit K Basu
Journal:  Pediatr Crit Care Med       Date:  2020-02       Impact factor: 3.624

4.  Urinary Angiotensinogen: A Promising Biomarker of AKI Progression in Acute Decompensated Heart Failure: What Does It Mean?

Authors:  Jan Wysocki; Daniel Batlle
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-18       Impact factor: 8.237

5.  Guiding AKI Prevention Using Biomarkers.

Authors:  Azra Bihorac
Journal:  Crit Connect       Date:  2015-04-02

Review 6.  The impact of biomarkers of acute kidney injury on individual patient care.

Authors:  Jay L Koyner; Alexander Zarbock; Rajit K Basu; Claudio Ronco
Journal:  Nephrol Dial Transplant       Date:  2020-08-01       Impact factor: 5.992

7.  Renal Failure Patients in Disasters.

Authors:  Kenneth D Lempert; Jeffrey B Kopp
Journal:  Disaster Med Public Health Prep       Date:  2019-05-06       Impact factor: 1.385

Review 8.  Renal dysfunction in acute congestive heart failure: a common problem for cardiologists and nephrologists.

Authors:  Giorgio Graziani; Daniela Pini; Silvia Oldani; David Cucchiari; Manuel Alfredo Podestà; Salvatore Badalamenti
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

9.  Serum Creatinine Trajectories for Community- versus Hospital-Acquired Acute Kidney Injury.

Authors:  David G Warnock; T Clark Powell; Edward D Siew; John P Donnelly; Henry E Wang; Ravindra L Mehta
Journal:  Nephron       Date:  2016-07-26       Impact factor: 2.847

Review 10.  Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review.

Authors:  Kady Phe; Emily L Heil; Vincent H Tam
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.